Esperion Therapeutics (ESPR) 8-K Summary

• Management Change: Esperion appointed John B. Harlow, Jr. as Chief Commercial Officer (CCO), effective November 17, 2025.
• Mr. Harlow previously served as CCO at Melinta Therapeutics.
• Compensation Highlights:
  • Annual Base Salary: $535,000.
  • Target Bonus: 45% of base.
  • One-time Sign-on Bonus: $35,000.
• Critical Equity Component: The appointment includes a substantial grant: 380,000 stock options and 424,536 Restricted Stock Units (RSUs), vesting over four years. > This move signals an executive focus